A Study Utilizing Escitalopram in Glioma Patients
Recruiting
Phase 2
Interventional Study
Glioma of Brain
Glioma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 20 (estimated)
- Sponsor
- University of Nebraska · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Glioma is a cancer of glial cells, a class of tissue supporting neuronal function in the brain. As many as 85% of glioma patients experience cognitive impairment. This is not only from direct tumor involvement, but also from therapy such as cranial radiation and chemotherapy, which degrades neuronal function. There is evidence that serotonin selective reuptake inhibitors (SSRIs), such as escitalop…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Pathologically proven diagnosis of Grade IV glioma
* Newly diagnosed disease to receive chemotherapy and/or radiation
* Performance status Eastern Cooperative Oncology Group (ECOG) 0-2 or equivalent
* 19 years of age or older
* Life expectancy greater than 6 months
* Able to p…
Contacts